Business Context and Reporting Period
This Form 8-K filing by Vivos Therapeutics, Inc. (VVOS) reports on events occurring on May 11, 2021, with the report filed on May 12, 2021. The Company, an emerging growth company incorporated in Delaware, announced the consummation of a follow-on, underwritten public offering of its common stock.
Key Financial Metrics
- Offering Size: 4,600,000 shares of Common Stock (including 600,000 shares from the full exercise of the underwriters' option).
- Offering Price: $6.00 per share.
- Gross Proceeds: $27,600,000 (before underwriting discounts, commissions, and estimated offering expenses).
- Net Proceeds: The filing text does not provide a clear value for net proceeds after deducting expenses.
- Debt and Liquidity: The filing text does not provide specific data on existing debt levels or overall liquidity positions outside of the new capital raised.
Material Changes
The primary material change is the increase in the Company's share count and cash position resulting from the Follow-on Offering. The Company entered into a new Underwriting Agreement with Roth Capital Partners, LLC, and issued a Representative's Warrant to the underwriters. No prior comparable period financial metrics are provided in this specific filing to calculate percentage changes in revenue or profit.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the closing of the offering. The filing references a press release (Exhibit 99.1) for further details but does not contain specific forward-looking guidance, risk factors, or contingency plans within the text of this report. The Company is identified as an emerging growth company, which may entail certain reporting exemptions.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses by reviewing the final prospectus or subsequent financial statements.
- Review the terms of the Representative's Warrant (Exhibit 4.1) to understand potential dilution and exercise conditions.
- Confirm the intended use of the $27.6 million in gross proceeds as detailed in the press release (Exhibit 99.1).
- Check the updated share count and fully diluted capitalization following the issuance of 4.6 million new shares.